GlassScriptPhysician profile
Wendy S Henninger
NPI 1710172838
$4,181.56
in general payments reported to CMS, 2019-2025
23 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $667 · 2022: $1,506 · 2023: $734 · 2024: $819 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.93 |
| Education | $250.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $772.82 | 2021-2022 | |
| Janssen Biotech, INC. | $487.95 | 2022-2024 | Darzalex, Tecvayli, Talvey |
| Karyopharm Therapeutics INC. | $422.54 | 2022-2025 | Xpovio |
| Astellas Pharma US INC | $416.33 | 2023-2025 | Cresemba, Vyloy, Padcev |
| E.R. Squibb & Sons, L.L.C. | $358.02 | 2022-2023 | Reblozyl |
| Sanofi-Aventis U.S. LLC | $324.52 | 2023-2024 | |
| Incyte Corporation | $290.95 | 2021-2024 | Jakafi |
| Daiichi Sankyo INC. | $253.78 | 2022 | |
| Blueprint Medicines Corporation | $124.99 | 2022 | |
| Pfizer INC. | $123.94 | 2025 | |
| Celgene Corporation | $123.15 | 2023-2025 | Breyanzi, Onureg |
| Merck Sharp & Dohme LLC | $95.17 | 2021-2023 | Keytruda, Lynparza |
| Jazz Pharmaceuticals INC. | $79.02 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $49.87 | 2022-2023 | Calquence, Tagrisso |
| Genzyme Corporation | $42.04 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $41.96 | 2025 | Tecvayli, Talvey, Carvykti |
| Legend Biotech USA INC. | $41.37 | 2024-2025 | Carvykti |
| Adaptive Biotechnologies Corporation | $33.07 | 2025 | Clonoseq |
| Glaxosmithkline, LLC. | $26.13 | 2023 | Shingrix |
| Abbott Laboratories | $23.52 | 2025 | Eterna |
| Regeneron Healthcare Solutions, INC. | $19.15 | 2023 | Libtayo |
| Seagen INC. | $16.84 | 2023 | Padcev |
| Teleflex LLC | $14.43 | 2024 | Vascband |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Henninger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.